Skip to main content
NewslettersWatchlist

Harmony Biosciences Holdings Inc(HRMY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low28.87
Day High29.56
Open:29.30
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
Motley Fool
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
Motley Fool
Why Harmony Biosciences Stock Got Slammed Today
Motley Fool
Harmony Biosciences (HRMY) Q3 2023 Earnings Call Transcript
PR Newswire
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023
Motley Fool
Why Shares of Harmony Bioscience Are Falling on Friday
PR Newswire
HARMONY BIOSCIENCES ANNOUNCES TOPLINE DATA FROM PHASE 3 INTUNE STUDY EVALUATING PITOLISANT IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA
PR Newswire
HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME
Motley Fool
2 Magnificent Growth Stocks to Buy Right Now
PR Newswire
HARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERS
PR Newswire
HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE
PR Newswire
HARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA
PR Newswire
HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION
OTOS Inc.
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar
PR Newswire
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Motley Fool
Harmony Biosciences (HRMY) Q2 2023 Earnings Call Transcript
PR Newswire
HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM
PR Newswire
HARMONY BIOSCIENCES ENTERS INTO $185 MILLION TERM LOAN FACILITY
PR Newswire
Harmony Biosciences Announces Funding for Unique Community Initiatives Through its Patients and Progress at the Heart Awards Programs
PR Newswire
HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION
PR Newswire
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS ON AUGUST 1, 2023
PR Newswire
HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023
PR Newswire
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 44th ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR Newswire
HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
PR Newswire
HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING
Motley Fool
Harmony Biosciences (HRMY) Q1 2023 Earnings Call Transcript
PR Newswire
HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER
PR Newswire
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 2, 2023
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
Business Wire
HARMONY ALERT: Bragar Eagel & Squire, P.C. is Investigating Harmony Biosciences Holdings, Inc. on Behalf of Harmony Stockholders and Encourages Investors to Contact the Firm
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

Profile

Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.